Overall, the data suggest that ganaxolone is efficacious in reducing seizure frequency in a variety of disorders, including CDKL5, Lennox-Gastaut syndrome, and PCDH19 patients. Here, CDKL5 is linked to Lennox-Gastaut syndrome.